-
Mesoblast Updates On Rexlemestrocel-L Program In Chronic Low Back Pain
Thursday, July 1, 2021 - 7:21am | 238Mesoblast Limited (NASDAQ: MESO) provided an update on the strategy for bringing rexlemestrocel-L to patients in the U.S. with chronic low back pain (CLBP) due to degenerative disc disease refractory to available therapies. The company has filed a request and expects to hold a Type...
-
Mesoblast Spikes On Positive Cell Therapy Data in Back Pain Study
Thursday, February 11, 2021 - 6:41am | 411Positive results from Mesoblast Limited’s (NASDAQ: MESO) chronic back pain treatment trial have boosted investor confidence sending the company’s shares higher in the premarket after an announcement showing its stem cell treatment for chronic lower back pain is “safe,...